Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Acute Interstitial Nephritis: Etiology, Pathogenesis, Diagnosis, Treatment and Prognosis
Sathick, Insara Jaffer , Zand, Ladan , Kamal, A. N. , Norby, Suzanne M. , Garovic, Vesna D.

Nephrology Research & Reviews | November 18, 2013 | Volume: 5 | Issue: 1 | Pages: 13-20

10.4081/nr.2013.e4 Get It

Acute interstitial nephritis (AIN) is an important and common cause of acute kidney injury, particularly in hospitalized patients. The classic presentation of AIN includes fever, rash, arthralgias, eosinophilia, and acute kidney injury. While renal biopsy is considered the gold standard for diagnosis, the clinical presentation of fever and rash along with laboratory evidence of peripheral blood eosinophilia, eosinophiluria, and low-grade proteinuria strongly suggest the diagnosis. Histologically, interstitial inflammation with interstitial edema and tubulitis is the hallmark of interstitial nephritis. The most common causative factors are drugs, infections, and certain immune-mediated disorders. Discontinuation of the offending agent is considered the mainstay of therapy while the use of corticosteroids to hasten renal recovery may be beneficial. The role of interstitial nephritis in the pathogenesis of chronic kidney disease and end-stage renal disease is increasingly recognized, further emphasizing the importance of its early diagnosis and timely treatment.
Clinical variability and additional mutations in amyotrophic lateral sclerosis patients with p.N352S mutations in TARDBP
Blitterswijk, Marka van , Rademakers, Rosa , Berg, Leonard H. van den , van Blitterswijk, Marka

Neuropathology and Applied Neurobiology | November 18, 2013 | Volume: 40 | Issue: 3 | Pages: 356-358

10.1111/nan.12099 | PMID 24237396 Get It

AT‐101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
Paulus, Aneel , Chitta, Kasyapa S., Akhtar, Sharoon , Personett, David, Miller, Kena C., Thompson, Kevin J. , Carr, Jennifer M., Kumar, Shaji , Ansell, Stephen M. , Dispenzieri, Angela , Reeder, Craig B. , Rivera, Candido E., Foran, James M. , Chanan‐Khan, Asher , Chitta, Kasyapa, Carr, Jennifer, Mikhael, Joseph R., Chanan-Khan, Asher, Roy, Vivek , Mıkhael, Joseph , Dispenzieri, Angela , Thompson, Kevin J , Paulus, Aneel

British Journal of Haematology | November 18, 2013 | Volume: 164 | Issue: 3 | Pages: 352-365

10.1111/bjh.12633 | PMID 24236538 Get It

SummaryMultiple myeloma, the second most common haematological malignancy in the U.S., is currently incurable. Disruption of the intrinsic apoptotic pathway by BCL2 and MCL1 upregulation is observed in >80% of myeloma cases and is associated with an aggressive clinical course. Remarkably, there is no approved drug with the ability to target BCL2 or MCL1. Thus, we investigated the anti‐tumour effects of a pan‐BCL2 inhibitor, AT‐101, which has high binding specificity for BCL2 and MCL1 in preclinical models of plasma cell cancers (Multiple myeloma and Waldenström macroglobulinaemia). Gene expression and immunoblot analysis of six plasma cell cancer models showed upregulation of BCL2 family members. AT‐101 was able to downregulate BCL2 and MCL1 in all plasma cell cancer models and induced apoptotic cell death in a caspase‐dependent manner by altering mitochondrial membrane permeability. This cytotoxic effect and BCL2 downregulation were further potentiated when AT‐101 was combined with lenalidomide/dexamethasone (LDA). NanoString nCounter mRNA quantification and Ingenuity Pathways Analysis revealed differential changes in the CCNA2, FRZB, FYN, IRF1, PTPN11 genes in LDA‐treated cells. In summary, we describe for the first time the cellular and molecular events associated with the use of AT‐101 in combination with lenalidomide/dexamethasone in preclinical models of plasma cell malignancy.
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium
Herránz, Jesús , Michailidou, Kyriaki , Zamora, M. Pilar , Pérez, José Ignacio Arias , González‐Neira, Anna , Pita, Guillermo , Alonso, M. Rosario, Wang, Qin , Bolla, Manjeet K. , Czene, Kamila , Eriksson, Mikael , Humphreys, Keith , Darabi, Hatef, Li, Jingmei , Hopper, John L. , Apicella, Carmel, Southey, Melissa C. , Chenevix‐Trench, Georgia , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Swerdlow, Anthony J. , Ashworth, Alan , Orr, Nicholas, Schoemaker, Minouk J. , Jakubowska, Anna , Lubiński, Jan , Jaworska–Bieniek, Katarzyna, Durda, Katarzyna, Andrulis, Irene L. , Knight, Julia A. , Glendon, Gord, Mulligan, Anna Marie , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Nevanlinna, Heli , Muranen, Taru , Aittomäki, Kristiina, Blomqvist, Carl , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Vachon, Celine M. , Purrington, Kristen S. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Grip, Mervi, Dunning, Alison M. , Shah, Mitul , Guénel, Pascal , Truong, Thérèse , Sanchez, Marie, Mulot, Claire , Brenner, Hermann , Dieffenbach, Aida Karina, Stegmaier, Christa, Lindblom, Annika , Margolin, Sara , Hooning, Maartje J. , Hollestelle, Antoinette , Collée, J. Margriet, Jager, Agnes , Cox, Angela , Brock, Ian W., Reed, Malcolm , Devilee, Peter , Tollenaar, Robert A.E.M., Seynaeve, Caroline, Haiman, Christopher A., Henderson, Brian E., Schumacher, Fredrick R. , Simard, Jacques , Dumont, Martine , Soucy, Penny, Dörk, Thilo , Bogdanova, Natalia , Hamann, Ute , Rüdiger, Thomas , Ulmer, Hans-Ulrich, Fasching, Peter A. , Häberle, Lothar , Ekici, Arif B. , Beckmann, Matthias W. , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Peto, Julian, Radice, Paolo , Peterlongo, Paolo , Peissel, Bernard , Mariani, P., Severi, Gianluca , Baglietto, Laura , Sawyer, Elinor J. , Tomlinson, Ian , Kerin, Michael J. , Miller, Nicola, Marmé, F., Burwinkel, Barbara , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli‐Matti , Hartikainen, Jaana M. , Lambrechts, Diether , Yesilyurt, Betül T., Floris, Giuseppe , Leunen, Karin, Alnæs, Grethe Grenaker, Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , García‐Closas, Montserrat , Lissowska, Jolanta , Figueroa, Jonine D. , Schmidt, Marjanka K. , Verhoef, Senno, Rutgers, Emiel J. , Brauch, Hiltrud , Brüning, Thomas , Ko, Yon‐Dschun, Network, The GENICA, TNBCC, The, Yannoukakos, Drakoulis , Malats, Núria , Easton, Douglas F. , Manoukian, Siranoush , Durocher, Francine , Zaffaroni, Daniela , Orr, Nick , Thorne, Heather , Bowtell, David D.L. , Rabstein, Sylvia , Lotz, Anne , Lambrechts, Diether , Milne, Roger L. , Dennis, Joe , Tyrer, Jonathan P. , Eriksson, Mikael , Anton‐Culver, Hoda , Neuhausen, Susan L. , Ziogas, Argyrios , Clarke, Christina A. , Dite, Gillian S. , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Orr, Nicholas, Rudolph, Anja , Seibold, Petra , Wang, Xianshu , Olson, Janet E. , Vachon, Celine M. , Sanchez, Marie, Arndt, Volker , Hooning, Maartje J. , Marchand, Loı̈c Le , Försti, Asta , Giles, Graham G. , Mannermaa, Arto, Chanock, Stephen Jacob , Broeks, Annegien , Network, The GENICA, Couch, Fergus J. , Toland, Amanda Ewart , TNBCC, The, Pharoah, Paul D.P. , Hall, Per N , Benı́tez, Javier , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Swerdlow, Anthony J , Radice, Paolo , Lissowska, Jolanta , Southey, Melissa C , Malats, Nuria , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Michailidou, Kyriaki , Hartikainen, Jaana M , Bogdanova, Natalia V , Simard, Jacques , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bowtell, David D , Pylkäs, Katri , Yannoukakos, Drakoulis , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Purrington, Kristen S , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick

Human Molecular Genetics | November 16, 2013 | Volume: 23 | Issue: 7 | Pages: 1934-1946

10.1093/hmg/ddt581 | PMID 24242184 Get It

Abstract Part of the substantial unexplained familial aggregation of breast cancer may be due to interactions between common variants, but few studies have had adequate statistical power to detect interactions of realistic magnitude. We aimed to assess all two-way interactions in breast cancer susceptibility between 70 917 single nucleotide polymorphisms (SNPs) selected primarily based on prior evidence of a marginal effect. Thirty-eight international studies contributed data for 46 450 breast cancer cases and 42 461 controls of European origin as part of a multi-consortium project (COGS). First, SNPs were preselected based on evidence (P < 0.01) of a per-allele main effect, and all two-way combinations of those were evaluated by a per-allele (1 d.f.) test for interaction using logistic regression. Second, all 2.5 billion possible two-SNP combinations were evaluated using Boolean operation-based screening and testing, and SNP pairs with the strongest evidence of interaction (P < 10−4) were selected for more careful assessment by logistic regression. Under the first approach, 3277 SNPs were preselected, but an evaluation of all possible two-SNP combinations (1 d.f.) identified no interactions at P < 10−8. Results from the second analytic approach were consistent with those from the first (P > 10−10). In summary, we observed little evidence of two-way SNP interactions in breast cancer susceptibility, despite the large number of SNPs with potential marginal effects considered and the very large sample size. This finding may have important implications for risk prediction, simplifying the modelling required. Further comprehensive, large-scale genome-wide interaction studies may identify novel interacting loci if the inherent logistic and computational challenges can be overcome.
An Unusual Retrocardiac Density
Malone, Jonathan C., Ussavarungsi, Kamonpun , Jolles, Howard, Johnson, Margaret M. , Malone, Jonathan C.

American Journal of Respiratory and Critical Care Medicine | November 15, 2013 | Volume: 188 | Issue: 10 | Pages: 1262-1262

10.1164/rccm.201302-0360im | PMID 24236589 Get It

The Dynamic Architectural and Epigenetic Nuclear Landscape: Developing the Genomic Almanac of Biology and Disease
Zaidi, Sayyed K. , Wu, Hai , Grandy, Rodrigo A. , Montecino, Martı́n , Wijnen, André J. van , Lian, Jane B. , Stein, Gary S., Stein, Janet L. , Tai, Phillip W.L. , van Wijnen, Andre J

Journal of Cellular Physiology | November 15, 2013 | Volume: 229 | Issue: 6 | Pages: 711-727

10.1002/jcp.24508 | PMID 24242872 Get It

Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis
Poshusta, Tanya L., Katoh, Nagaaki , Dispenzieri, Angela , Ramı́rez-Alvarado, Marina , Gertz, Morie A. , Dispenzieri, Angela , Ramirez-Alvarado, Marina

International Journal of Molecular Sciences | November 15, 2013 | Volume: 14 | Issue: 11 | Pages: 22604-22617

10.3390/ijms141122604 | PMID 24248061 Get It

Light chain (AL) amyloidosis is a devastating disease characterized by amyloid deposits formed by immunoglobulin light chains. Current available treatments involve conventional chemotherapy and autologous stem cell transplant. We have recently concluded a phase III trial comparing these two treatments. AL amyloidosis patients who achieve hematological complete response (CR) do not necessarily achieve organ response regardless of the treatment they received. In order to investigate the possible correlation between amyloid formation kinetics and organ response, we selected AL amyloidosis patients from the trial with kidney involvement and CR after treatment. Six patients were selected and their monoclonal immunoglobulin light chains were characterized. The proteins showed differences in their stability and their kinetics of amyloid formation. A correlation was detected at pH 7.4, showing that less stable proteins are more likely to form amyloid fibrils. AL-T03 is too unstable to form amyloid fibrils at pH 7.4. This protein was found in the only patient in the study that had organ response, suggesting that partially folded species are required for amyloid formation to occur in AL amyloidosis.
Editorial Comment
Husmann, Douglas A. , Husmann, Douglas

Journal of Urology | November 15, 2013 | Volume: 191 | Issue: 2 | Pages: 450-450

10.1016/j.juro.2013.08.121 | PMID 24239864 Get It

LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner
Ohkawara, Bisei , Cabrera‐Serrano, Macarena , Nakata, Tomohiko, Milone, Margherita , Asai, Nobuyuki, Ito, Kenyu , Ito, Yasutomo, Engel, Andrew G. , Ohno, Kinji , Ito, Mikako , Masuda, Akio

Human Molecular Genetics | November 15, 2013 | Volume: 23 | Issue: 7 | Pages: 1856-1868

10.1093/hmg/ddt578 | PMID 24234652 Get It

Abstract Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Using Sanger and exome sequencing in a CMS patient, we identified two heteroallelic mutations, p.Glu1233Lys and p.Arg1277His, in LRP4 coding for the postsynaptic low-density lipoprotein receptor-related protein 4. LRP4, expressed on the surface of the postsynaptic membrane of the neuromuscular junction, is a receptor for neurally secreted agrin, and LRP4 bound by agrin activates MuSK. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR on the postsynaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the neuromuscular junction. LRP4 also functions as an inhibitor of Wnt/beta-catenin signaling. The identified mutations in LRP4 are located at the edge of its 3rd beta-propeller domain and decrease binding affinity of LRP4 for both MuSK and agrin. Mutations in the LRP4 3rd beta-propeller domain were previously reported to impair Wnt signaling and cause bone diseases including Cenani–Lenz syndactyly syndrome and sclerosteosis-2. By analyzing naturally occurring and artificially introduced mutations in the LRP4 3rd beta-propeller domain, we show that the edge of the domain regulates the MuSK signaling whereas its central cavity governs Wnt signaling. We conclude that LRP4 is a new CMS disease gene and that the 3rd beta propeller domain of LRP4 mediates the two signaling pathways in a position-specific manner.
H alomonas sulfidaeris ‐dominated microbial community inhabits a 1.8 km‐deep subsurface C ambria
Dong, Yiran , Kumar, Charu G., Kim, Pan‐Jun , Miller, P., Price, Nathan D. , Flynn, Theodore M. , Sanford, Robert A. , Krapac, Ivan G., Locke, Randall A. , Hong, Pei‐Ying , Tamaki, Hideyuki , Mackie, Roderick I. , Hernandez, Alvaro G. , Wright, Chris , Mikel, Mark A. , Walker, Jared, Sivaguru, Mayandi , Fried, Glenn , Yannarell, Anthony C. , Fouke, Bruce W. , Chia, Nicholas , Cann, Isaac , Liu, Wen‐Tso , Price, Nathan D

Environmental Microbiology | November 14, 2013 | Volume: 16 | Issue: 6 | Pages: 1695-1708

10.1111/1462-2920.12325 | PMID 24238218 Get It

Summary A low‐diversity microbial community, dominated by the γ ‐proteobacterium H alomonas sulfidaeris , was detected in samples of warm saline formation porewater collected from the C ambrian Mt. S imon S andstone in the I llinois B asin of the N orth A merican M idcontinent (1.8 km/5872 ft burial depth, 50° C , pH 8, 181 bars pressure). These highly porous and permeable quartz arenite sandstones are directly analogous to reservoirs around the world targeted for large‐scale hydrocarbon extraction, as well as subsurface gas and carbon storage. A new downhole low‐contamination subsurface sampling probe was used to collect in situ formation water samples for microbial environmental metagenomic analyses. Multiple lines of evidence suggest that this H . sulfidaeris ‐dominated subsurface microbial community is indigenous and not derived from drilling mud microbial contamination. Data to support this includes V 1‐ V 3 pyrosequencing of formation water and drilling mud, as well as comparison with previously published microbial analyses of drilling muds in other sites. Metabolic pathway reconstruction, constrained by the geology, geochemistry and present‐day environmental conditions of the Mt . S imon S andstone, implies that H . sulfidaeris ‐dominated subsurface microbial community may utilize iron and nitrogen metabolisms and extensively recycle indigenous nutrients and substrates. The presence of aromatic compound metabolic pathways suggests this microbial community can readily adapt to and survive subsurface hydrocarbon migration.